Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SQLE | Q14534 | 1/20 | 0.32 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.32 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.32 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 1,4-Butanediol SCHEMBL6334524 | 1.00 | SMN1; SMN2 (0.47) | SMN1; SMN2TSHRLMNAALDH1A1HSD17B10 | |
| 1,4-Butanediol SCHEMBL5903369 | 1.00 | — | — | |
| 1,4-Butanediol SCHEMBL10941995 | 0.96 | SMN1; SMN2 (0.44) | SMN1; SMN2TSHRLMNAALDH1A1HSD17B10 | |
| 1,6-Hexanediol SCHEMBL29249024 | 0.96 | TSHR (0.50) | SMN1; SMN2TSHRLMNAALDH1A1HSD17B10 | |
| Propene SCHEMBL28542606 | 0.96 | TSHR (0.50) | SMN1; SMN2TSHRLMNAALDH1A1HSD17B10 | |
| 1,4-Butanediol SCHEMBL1425714 | 0.96 | SMN1; SMN2 (0.44) | SMN1; SMN2TSHRLMNAALDH1A1HSD17B10 | |
| 1,4-Butanediol SCHEMBL5429731 | 0.96 | SMN1; SMN2 (0.44) | SMN1; SMN2TSHRLMNAALDH1A1HSD17B10 | |
| 1,6-Hexanediol SCHEMBL21353993 | 0.96 | TSHR (0.50) | SMN1; SMN2TSHRLMNAALDH1A1HSD17B10 | |
| 1,6-Hexanediol SCHEMBL22977579 | 0.96 | TSHR (0.50) | SMN1; SMN2TSHRLMNAALDH1A1HSD17B10 | |
| 1,6-Hexanediol SCHEMBL16970400 | 0.93 | TSHR (0.47) | SMN1; SMN2TSHRLMNAALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140037713-A1 | TRANSDERMAL COMPOSITIONS FOR ANTI-CHOLINERGIC AGENTS | ANTARES PHARMA IPL, AG (CH) | 2014-02-06 | — | — | US | disclosed |
| US-20120035385-A1 | SELECTING CATALYST AND CONDITIONS | RINARD CHAUNCEY J (US) | 2012-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035385-A1 | SELECTING CATALYST AND CONDITIONS | ALG3, MMS19, CAD | SMN1; SMN2 2175/4885TSHR 4586/4885LMNA 1506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.